Seventure Partners is a French venture capital firm targeting in Tech/Digital and Life Sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion. Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with € 1 billion under management as of December 31, 2023. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations. Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors. The different funds/verticals on which Seventure Partners are focusing on today: - Life Sciences : Biotech, Healthcare, Nutrition - Tech/Digital : B2B SaaS, Fintech, Retailtech, Cybersecurity - Sports & Wellbeing - Blue Economy
Anybuddy is a leading sports booking marketplace in France, specializing in racket sports. The company has developed a sports application that allows users to find players and book pitches for football and tennis matches. Its platform provides access to numerous clubs, facilitating reservations and payments without requiring a license or subscription. Users can access a wide selection of quality tennis courts and various playing surfaces, all at competitive prices. Anybuddy aims to simplify the process of booking sports facilities and encourage more participation in physical activities.
Syroco
Series A in 2024
Syroco is a scientific and technical laboratory based in Marseille, France, established in 2019. The company focuses on enhancing efficiency in the energy and transportation sectors through innovative solutions. Syroco specializes in developing a speed craft with the aim of breaking sailing speed records and engages in projects that involve designing and building advanced engineering systems. The team comprises diverse professionals, including a kitesurfer, a two-time world sailing speed record holder, digital entrepreneurs, and a naval architect. Syroco's approach includes tackling "moonshot challenges," which are ambitious technological endeavors. Additionally, the company employs data and artificial intelligence to create modeling software that supports the energy transition in maritime transportation, facilitating the optimization of operational and energy efficiency for both on-board and shore applications.
Aenitis Technologies
Venture Round in 2024
Aenitis Technologies is a French start-up founded in July 2014 by Mauricio Hoyos and Jean-Luc Aider, both researchers associated with the CNRS at the PMMH Laboratory in Paris. The company specializes in the development of medical devices aimed at enhancing cell therapy preparations. By utilizing acoustophoresis technologies, Aenitis Technologies creates innovative solutions for the separation, manipulation, and filtration of biological elements. Their focus is on addressing challenges faced by cell therapy units and blood banks, particularly in areas such as cell sorting, washing, and isolation. Aenitis Technologies aspires to lead the market in filtering and separating solutions through their advanced acoustic preparation techniques, with the ultimate goal of revolutionizing practices in public health.
MaaT Pharma
Post in 2024
MaaT Pharma is a clinical-stage biotechnology company based in Lyon, France, founded in 2014. It specializes in developing therapies aimed at treating diseases associated with gut microbiota imbalance, particularly in the context of cancer and Graft-versus-Host Disease, a complication related to stem cell transplantation. The company has made significant advancements in its research, achieving proof of concept in patients with acute myeloid leukemia. MaaT Pharma employs a comprehensive approach to restore microbiome symbiosis, which has implications for enhancing survival outcomes in life-threatening conditions. Additionally, it has developed a proprietary platform called GutPrint®, which is instrumental in evaluating drug candidates and identifying biomarkers for microbiome-related diseases, thereby supporting the expansion of its therapeutic pipeline, including improvements in immunotherapy for solid tumors.
Nexess
Venture Round in 2024
Nexess SAS is a company that specializes in developing and selling security management solutions tailored for nuclear and Seveso-type plants. Founded in 2006 and based in Mougins, France, with an additional office in Paris, the company offers a range of products including NexLink, a software platform designed to enhance security and productivity. Its offerings also encompass various identification products such as personal security badges, RFID tags, and mobile devices, along with smart camera systems that provide autonomous image analysis and real-time data transmission. Nexess's solutions are utilized for applications like hazardous product traceability, managing smart secured cabinets, site localization, and monitoring access to hazardous zones. By integrating technologies such as RFID, Nexess supports major digital transformation projects, enhancing clients' performance in productivity, quality, and security.
Eligo Bioscience
Series B in 2023
Eligo Bioscience S.A.S is a biotechnology company based in Paris, France, that specializes in the development of Eligobiotics, a new class of antimicrobials designed to target specific bacteria based on their genetic makeup. Founded in 2014, the company utilizes a combination of CRISPR/Cas technology and engineered phage capsids to create antibiotics capable of addressing microbiome-related diseases and combating resistant pathogens. These programmed antimicrobials aim to eradicate virulent bacteria within the human microbiome, facilitating the creation of advanced therapeutics for conditions caused by superbugs. Eligo Bioscience's innovative approach positions it at the forefront of microbiome precision therapies and next-generation antibiotic solutions.
Mediarithmics
Venture Round in 2023
Mediarithmics is a cloud-based data marketing platform headquartered in Fontenay-sous-Bois, France, that was established in 2011. It provides a solution for brands to manage retargeting campaigns across multiple devices and enables agencies to handle clients' real-time bidding (RTB) and email campaigns through a unified tool. The platform functions as a next-generation Customer Data Platform (CDP) that encompasses all aspects of Data Management Platforms (DMP) and CDPs. It facilitates the creation of Data Alliances, ensuring data security and compliance with regulations. Mediarithmics' technology allows for the collection of comprehensive customer and prospect data, enabling real-time segmentation and activation of multi-channel marketing campaigns. Clients can also customize the platform by incorporating their own algorithms to enhance marketing personalization and data monetization strategies. Overall, Mediarithmics aims to improve consumer engagement and drive growth through data-driven outreach strategies.
Domain Therapeutics
Series A in 2022
Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-Allâ„¢ to identify orthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-Allâ„¢ is able to address difficult GPCRs such as orphan and peptidic GPCRs.
HARDLOOP
Venture Round in 2022
HARDLOOP SARL is an online retailer based in Paris, France, specializing in sports products and adventure gear. Founded in 2014, the company offers a wide range of items, including shoes, gloves, bottles, and various accessories tailored for outdoor activities such as hiking, trail running, skiing, climbing, and swimming. By providing a diverse selection from international brands, HARDLOOP aims to equip sports enthusiasts with the necessary gear for their adventures. The platform facilitates easy access to quality sports apparel and accessories, catering to the needs of active individuals seeking to enhance their outdoor experiences.
SportEasy
Series A in 2021
SportEasy is a user-friendly web and mobile application designed to assist amateur sports teams in managing their activities. Launched in France in 2011, the platform enables coaches to organize games and practices, communicate effectively with players, and analyze team statistics. It also includes social features that allow players to engage with teammates through activities like voting for the player of the game and sharing photos. Available in both French and English, SportEasy aims to streamline the administrative tasks associated with sports management, allowing coaches, managers, and volunteers to focus more on the field and less on paperwork. While the basic features of the application are free, premium plans for teams and clubs have been introduced to provide additional functionality.
Expensya
Series B in 2021
Expensya SAS, founded in 2014 and based in Paris, France, specializes in expense management software solutions. Its flagship product, the Expensya application, is a web and mobile platform that automates the management of professional expense reports from receipt processing to archiving. The software incorporates advanced technologies such as Cloud computing, Artificial Intelligence, and Big Data to enhance efficiency in expense management. It offers features including expense tracking, data export, accountant integration, approval workflows, and mileage management, while also supporting local accounting regulations in approximately fifty countries. The platform is available in eight languages, catering to the diverse needs of businesses and simplifying the claims process.
Enterome
Series E in 2020
Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, the company specializes in developing innovative disease management solutions that leverage the understanding of the gut microbiome. Enterome focuses on creating biomarkers, companion diagnostics, and therapeutics targeted at microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company’s OncoMimic technology addresses cancer by mimicking tumor-associated antigens, thereby inducing a strong immune response against solid tumors. Enterome's drug candidates are designed to modulate the immune system and are currently advancing through clinical trials, with several programs in Phase 2 targeting challenging cancers such as glioblastoma, adrenal malignancies, and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts.
Scipio Bioscience
Series A in 2020
Scipio Bioscience is a biotechnology company based in Paris, France, founded in 2017. The company specializes in manufacturing benchtop kits that provide a sample preparation solution for single-cell studies. These kits are designed for use in sequencing applications within both clinical and basic research, particularly in the field of transcriptomics. Scipio Bioscience's innovative products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating advanced analysis and research in the life sciences.
MaaT Pharma
Series B in 2020
MaaT Pharma is a clinical-stage biotechnology company based in Lyon, France, founded in 2014. It specializes in developing therapies aimed at treating diseases associated with gut microbiota imbalance, particularly in the context of cancer and Graft-versus-Host Disease, a complication related to stem cell transplantation. The company has made significant advancements in its research, achieving proof of concept in patients with acute myeloid leukemia. MaaT Pharma employs a comprehensive approach to restore microbiome symbiosis, which has implications for enhancing survival outcomes in life-threatening conditions. Additionally, it has developed a proprietary platform called GutPrint®, which is instrumental in evaluating drug candidates and identifying biomarkers for microbiome-related diseases, thereby supporting the expansion of its therapeutic pipeline, including improvements in immunotherapy for solid tumors.
HARDLOOP
Venture Round in 2020
HARDLOOP SARL is an online retailer based in Paris, France, specializing in sports products and adventure gear. Founded in 2014, the company offers a wide range of items, including shoes, gloves, bottles, and various accessories tailored for outdoor activities such as hiking, trail running, skiing, climbing, and swimming. By providing a diverse selection from international brands, HARDLOOP aims to equip sports enthusiasts with the necessary gear for their adventures. The platform facilitates easy access to quality sports apparel and accessories, catering to the needs of active individuals seeking to enhance their outdoor experiences.
TIBOT Technologies
Seed Round in 2019
TIBOT Technologies SAS, established in 2016 and based in Cesson-Sévigné, France, specializes in designing and developing robotic solutions for poultry farming. The company focuses on enhancing the daily operations of poultry farmers through innovative technology. Its flagship products include Spoutnic, an assistant robot, and Spoutnic NAV, which autonomously scrapes, drinks, and feeds poultry. These robots are designed to improve animal welfare, increase hatching rates, and optimize working conditions for farmers, ultimately enhancing profitability in poultry operations. TIBOT Technologies aims to facilitate the poultry farming process by integrating automation and efficiency into traditional farming practices.
Expensya
Venture Round in 2018
Expensya SAS, founded in 2014 and based in Paris, France, specializes in expense management software solutions. Its flagship product, the Expensya application, is a web and mobile platform that automates the management of professional expense reports from receipt processing to archiving. The software incorporates advanced technologies such as Cloud computing, Artificial Intelligence, and Big Data to enhance efficiency in expense management. It offers features including expense tracking, data export, accountant integration, approval workflows, and mileage management, while also supporting local accounting regulations in approximately fifty countries. The platform is available in eight languages, catering to the diverse needs of businesses and simplifying the claims process.
Presto Engineering
Venture Round in 2018
Presto Engineering, Inc. is a provider of outsourced development operations for semiconductor and Internet of Things (IoT) device companies. Founded in 2006 and headquartered in San Jose, California, the company specializes in turn-key solutions that encompass radio-frequency (RF), mixed-signal devices, and comprehensive semiconductor testing and analysis services. Its offerings include wafer fabrication, back-end processing, and various backend packaging services. Additionally, Presto Engineering provides extensive product engineering, debugging, and release acceleration services, which cover testing, reliability assessments, and yield enhancement. The company serves a diverse range of sectors, including medical, automotive, industrial, and communications. With additional offices in France, Thailand, and Taiwan, Presto Engineering aims to help clients minimize overhead, reduce risk, and expedite their time-to-market.
Launchmetrics
Venture Round in 2018
Launchmetrics is a marketing platform and analytics solution provider focused on the fashion, luxury, and cosmetics sectors. Founded in 2006 and based in New York, with operational headquarters in Paris, the company offers a suite of products, including Samples, Events, Contacts, Discover, and Influencers, designed to enhance brand performance and streamline processes. Launchmetrics helps clients, which include prominent names like Dior, Fendi, and NET-A-PORTER, effectively engage with press and influencers, thereby accelerating their market launch and boosting brand visibility. The company collaborates with over 1,000 brands and partners such as IMG and the British Fashion Council, leveraging technology to create measurable marketing experiences that resonate with modern consumers. With a strong presence in eight markets and support in five languages, Launchmetrics is recognized as a trusted technology leader in the industry, serving about 50% of the top 100 luxury brands worldwide.
MDoloris Medical Systems
Private Equity Round in 2018
MDoloris Medical Systems SAS is a French company founded in 2010, specializing in the development and manufacturing of medical devices aimed at monitoring and alleviating patient pain. The company’s flagship product, the Analgesia Nociception Index (ANI) monitor, measures the activity of the autonomic nervous system to provide insights into patient pain levels, particularly for those who are non-communicative, such as those under general anesthesia or in intensive care. Additional offerings include ANI sensors and PhysioDoloris monitors, which are utilized across various healthcare settings, including surgical wards, ICUs, obstetrics, and neonatal care units. MDoloris also provides after-sales service to support its products. The company focuses on improving patient outcomes by enabling clinicians to better manage analgesic administration and assess patients’ comfort levels.
Enterome
Debt Financing in 2018
Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, the company specializes in developing innovative disease management solutions that leverage the understanding of the gut microbiome. Enterome focuses on creating biomarkers, companion diagnostics, and therapeutics targeted at microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company’s OncoMimic technology addresses cancer by mimicking tumor-associated antigens, thereby inducing a strong immune response against solid tumors. Enterome's drug candidates are designed to modulate the immune system and are currently advancing through clinical trials, with several programs in Phase 2 targeting challenging cancers such as glioblastoma, adrenal malignancies, and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts.
LNC Therapeutics
Series C in 2017
LNC Therapeutics is developing gut microbiota directed drugs to target obesity and associated cardiometabolic diseases. All projects encompass fundamental research, preclinical studies and clinical trials. Backed by leading venture capital investors, such as Seventure Partners (with the microbiome dedicated vehicle Health for Life Capital) and Family Offices, the company cultivates worldwide collaborations with renowned medical experts to ensure the highest level of standards in the development of innovative drugs. With a total of € 16.5 million raised so far including € 1.5 million grants from French BPI and Aquitaine Region, LNC Therapeutics will pursue its research programs to bring the next generation approach to treat obesity and cardiometabolic diseases.
Eligo Bioscience
Series A in 2017
Eligo Bioscience S.A.S is a biotechnology company based in Paris, France, that specializes in the development of Eligobiotics, a new class of antimicrobials designed to target specific bacteria based on their genetic makeup. Founded in 2014, the company utilizes a combination of CRISPR/Cas technology and engineered phage capsids to create antibiotics capable of addressing microbiome-related diseases and combating resistant pathogens. These programmed antimicrobials aim to eradicate virulent bacteria within the human microbiome, facilitating the creation of advanced therapeutics for conditions caused by superbugs. Eligo Bioscience's innovative approach positions it at the forefront of microbiome precision therapies and next-generation antibiotic solutions.
Intento Design
Series B in 2017
The company is to research aimed at developing a new analog design methodology at Laboratoire d’Informatique de Paris 6 in Paris, France. The research resulted in an extensive portfolio of intellectual property, including an innovative EDA tool that accelerates the design cycle by automating the sizing and migration of analog and mixed-signal circuitry used in complex SoCs for a variety of connected applications.
TargEDys
Series A in 2017
TargEDys is a company based in Rouen, France, that specializes in developing innovative treatments for eating disorders such as hyperphagia and anorexia. Established in 2011, TargEDys focuses on harnessing hormone mimetic proteins associated with the gut microbiota to regulate appetite. Their approach involves utilizing natural bacterial proteins found in the gut microbiome to modulate eating behavior, helping to control appetite in overweight individuals and restore normal eating patterns in elderly or cachexic patients. Through its research and development efforts, TargEDys aims to provide effective solutions for those struggling with metabolic diseases related to appetite regulation.
Business Table
Venture Round in 2017
Business Table is the leader in corporate dining and corporate events, with more than 30,000 service providers, including 15,000 restaurants, 1,500 caterers and 14,000 hotels and locations across France. This innovative solution launched in 2012 allows companies, from large groups to SMEs, to streamline the management of meal costs through a simple, innovative and efficient booking, ordering and invoicing tool. To expand its service offering, Business Table has partnered with American Express, Concur, Edenred and AirPlus
Enterome
Series D in 2017
Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, the company specializes in developing innovative disease management solutions that leverage the understanding of the gut microbiome. Enterome focuses on creating biomarkers, companion diagnostics, and therapeutics targeted at microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company’s OncoMimic technology addresses cancer by mimicking tumor-associated antigens, thereby inducing a strong immune response against solid tumors. Enterome's drug candidates are designed to modulate the immune system and are currently advancing through clinical trials, with several programs in Phase 2 targeting challenging cancers such as glioblastoma, adrenal malignancies, and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts.
Enterome
Series C in 2016
Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, the company specializes in developing innovative disease management solutions that leverage the understanding of the gut microbiome. Enterome focuses on creating biomarkers, companion diagnostics, and therapeutics targeted at microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company’s OncoMimic technology addresses cancer by mimicking tumor-associated antigens, thereby inducing a strong immune response against solid tumors. Enterome's drug candidates are designed to modulate the immune system and are currently advancing through clinical trials, with several programs in Phase 2 targeting challenging cancers such as glioblastoma, adrenal malignancies, and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts.
MaaT Pharma
Series A in 2016
MaaT Pharma is a clinical-stage biotechnology company based in Lyon, France, founded in 2014. It specializes in developing therapies aimed at treating diseases associated with gut microbiota imbalance, particularly in the context of cancer and Graft-versus-Host Disease, a complication related to stem cell transplantation. The company has made significant advancements in its research, achieving proof of concept in patients with acute myeloid leukemia. MaaT Pharma employs a comprehensive approach to restore microbiome symbiosis, which has implications for enhancing survival outcomes in life-threatening conditions. Additionally, it has developed a proprietary platform called GutPrint®, which is instrumental in evaluating drug candidates and identifying biomarkers for microbiome-related diseases, thereby supporting the expansion of its therapeutic pipeline, including improvements in immunotherapy for solid tumors.
HorseCom
Seed Round in 2016
HorseCom SAS, established in 2015 and based in Caen, France, specializes in Bluetooth audio headset technology tailored for horses and riders. The company's innovative products aim to enhance the well-being, performance, and connection between horses and their riders. HorseCom has developed a patented wearable device that diffuses music to both the horse and rider, fostering stronger bonds and improved synchronization during training and competition. This technology includes a Bluetooth earpiece for the rider, a cap with a Bluetooth receiver, earphones designed for equine ears, and a mobile application. By focusing on the welfare of horses, HorseCom's solutions promote recovery and reduce stress in anxiety-inducing situations, ultimately contributing to better training outcomes in equestrian sports.
Intento Design
Venture Round in 2015
The company is to research aimed at developing a new analog design methodology at Laboratoire d’Informatique de Paris 6 in Paris, France. The research resulted in an extensive portfolio of intellectual property, including an innovative EDA tool that accelerates the design cycle by automating the sizing and migration of analog and mixed-signal circuitry used in complex SoCs for a variety of connected applications.
MaaT Pharma
Seed Round in 2015
MaaT Pharma is a clinical-stage biotechnology company based in Lyon, France, founded in 2014. It specializes in developing therapies aimed at treating diseases associated with gut microbiota imbalance, particularly in the context of cancer and Graft-versus-Host Disease, a complication related to stem cell transplantation. The company has made significant advancements in its research, achieving proof of concept in patients with acute myeloid leukemia. MaaT Pharma employs a comprehensive approach to restore microbiome symbiosis, which has implications for enhancing survival outcomes in life-threatening conditions. Additionally, it has developed a proprietary platform called GutPrint®, which is instrumental in evaluating drug candidates and identifying biomarkers for microbiome-related diseases, thereby supporting the expansion of its therapeutic pipeline, including improvements in immunotherapy for solid tumors.
Mailjet
Series B in 2015
Mailjet is an email service provider founded in France in 2010, specializing in marketing and transactional emails. With a global client base of over 26,000 across 156 countries, Mailjet facilitates the sending of nearly 1 billion emails monthly. The company offers a comprehensive platform that includes analytics tools and APIs, allowing users to efficiently create, send, and optimize their email communications. Mailjet's proprietary technology and consulting services focus on maximizing email deliverability. The platform features innovative options such as A/B testing and campaign comparison to enhance customer engagement. Additionally, their support team provides assistance in multiple languages, including English, French, German, and Spanish, ensuring that clients receive timely help with their inquiries.
Eligo Bioscience
Seed Round in 2015
Eligo Bioscience S.A.S is a biotechnology company based in Paris, France, that specializes in the development of Eligobiotics, a new class of antimicrobials designed to target specific bacteria based on their genetic makeup. Founded in 2014, the company utilizes a combination of CRISPR/Cas technology and engineered phage capsids to create antibiotics capable of addressing microbiome-related diseases and combating resistant pathogens. These programmed antimicrobials aim to eradicate virulent bacteria within the human microbiome, facilitating the creation of advanced therapeutics for conditions caused by superbugs. Eligo Bioscience's innovative approach positions it at the forefront of microbiome precision therapies and next-generation antibiotic solutions.
Augure
Series E in 2015
Augure by Launchmetrics' software and social data help brands and agencies to bridge the gap between traditional PR and Influencer Marketing. Every day, more than 1,000 Communication, PR, and Public Affairs teams use the Publisher platform to engage relevant influencers, manage their campaigns, improve efficiency and increase their presence in the media and on social networks. The Augure by Launchmetrics' data services team compliments the Publisher software as the people behind the technology, offering consulting services that help clients to make sense of the data and apply it to their Influencer Marketing strategies. Founded in 2002 in Paris, Augure operates in Europe and Latin America. Its clients include Orange, Thales, AG Insurance, Pierre & Vacances, Château de Versailles, Amalthea, Hill+Knowlton and many others that span across the corporate sector.
Aenitis Technologies
Seed Round in 2015
Aenitis Technologies is a French start-up founded in July 2014 by Mauricio Hoyos and Jean-Luc Aider, both researchers associated with the CNRS at the PMMH Laboratory in Paris. The company specializes in the development of medical devices aimed at enhancing cell therapy preparations. By utilizing acoustophoresis technologies, Aenitis Technologies creates innovative solutions for the separation, manipulation, and filtration of biological elements. Their focus is on addressing challenges faced by cell therapy units and blood banks, particularly in areas such as cell sorting, washing, and isolation. Aenitis Technologies aspires to lead the market in filtering and separating solutions through their advanced acoustic preparation techniques, with the ultimate goal of revolutionizing practices in public health.
Open Ocean
Seed Round in 2015
Open Ocean SAS is a company that specializes in developing a SaaS-based decision-making platform focused on managing offshore infrastructure and marine operations. Founded in 2011 and headquartered in Paris and Brest, the company offers a range of products and services, including the Metocean Analytics solution, which analyzes atmospheric and oceanic conditions, and a detailed report on the tidal energy market in France. Additionally, Open Ocean provides a spectral wave database for Scotland, facilitating the development of marine renewable energy. Its services encompass site data analysis, resource and energy assessment, environmental data for design calculations, and research and development for offshore energy projects. Open Ocean caters to farm developers, operators, and public agencies within the renewable marine energy sector, leveraging a highly qualified team of oceanographers skilled in high-resolution modeling and data analysis.
MaaT Pharma
Seed Round in 2015
MaaT Pharma is a clinical-stage biotechnology company based in Lyon, France, founded in 2014. It specializes in developing therapies aimed at treating diseases associated with gut microbiota imbalance, particularly in the context of cancer and Graft-versus-Host Disease, a complication related to stem cell transplantation. The company has made significant advancements in its research, achieving proof of concept in patients with acute myeloid leukemia. MaaT Pharma employs a comprehensive approach to restore microbiome symbiosis, which has implications for enhancing survival outcomes in life-threatening conditions. Additionally, it has developed a proprietary platform called GutPrint®, which is instrumental in evaluating drug candidates and identifying biomarkers for microbiome-related diseases, thereby supporting the expansion of its therapeutic pipeline, including improvements in immunotherapy for solid tumors.
Streamdata.io
Series B in 2013
Streamdata.io is a developer of real-time API management software focused on event-driven infrastructure. Founded in 2008 and headquartered in Meylan, France, the company, previously known as Mobile Service SAS, operates as a subsidiary of Axway Software SA. Streamdata.io offers three primary services: Distribute, Journey, and Discover. Distribute enables the consumption and publication of events alongside APIs, transforming traditional request/response models into streams of events. Journey provides consulting services and a platform to assist companies in managing their API lifecycle, while Discover helps organizations catalog their digital assets to design effective APIs. The company has collaborated with various partners, including Xignite and Salesforce, to enhance its offerings. Streamdata.io has received multiple accolades, including the European Data Award in 2016 and recognition as a top startup in France. Additionally, the company contributes to industry standards such as AsynchAPI and OpenAPI, emphasizing its commitment to advancing API technology.
Nexess
Venture Round in 2013
Nexess SAS is a company that specializes in developing and selling security management solutions tailored for nuclear and Seveso-type plants. Founded in 2006 and based in Mougins, France, with an additional office in Paris, the company offers a range of products including NexLink, a software platform designed to enhance security and productivity. Its offerings also encompass various identification products such as personal security badges, RFID tags, and mobile devices, along with smart camera systems that provide autonomous image analysis and real-time data transmission. Nexess's solutions are utilized for applications like hazardous product traceability, managing smart secured cabinets, site localization, and monitoring access to hazardous zones. By integrating technologies such as RFID, Nexess supports major digital transformation projects, enhancing clients' performance in productivity, quality, and security.
Recommerce Group
Venture Round in 2013
Recommerce Group specializes in providing trade-in and remarketing solutions for second-hand mobile phones across Europe. The company focuses on the refurbishment and resale of smartphones, employing innovative proprietary technologies to enhance the lifecycle of these devices. Its services encompass a comprehensive range of solutions, including multi-channel trade-in options, reverse logistics, data erasure, and customer support, along with marketing and e-commerce support. Recommerce Group also offers rental services for smartphones and tablets, catering to diverse clients such as mobile operators, distributors, e-tailers, and manufacturers. With a strong presence in France, Spain, Switzerland, and Poland, the company collaborates with notable retailers and mobile network operators to promote sustainable practices in the electronics market. Founded in 2009 and headquartered in Paris, Recommerce Group is dedicated to giving smartphones a second life while providing affordable access to quality electronics.
TxCell
Series C in 2012
TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in the development of cellular immunotherapies utilizing regulatory T cells (Tregs) to address severe inflammatory and autoimmune diseases. The company's innovative therapies include TX200, a CAR-Treg-based treatment aimed at preventing graft rejection in solid organ transplantation. TxCell is also focused on developing CAR-Treg therapies for conditions such as bullous pemphigoid, multiple sclerosis, and refractory Crohn's disease, with ongoing clinical studies demonstrating promising results. The company collaborates with various research institutions, including the Lübeck Institute of Experimental Dermatology and the University of British Columbia, to enhance its research and development efforts. Additionally, TxCell is a subsidiary of Sangamo Therapeutics, having transitioned from its origins as a spin-off of Inserm, France's National Institute for Health and Medical Research.
Biophytis
Series B in 2012
Biophytis SA is a clinical-stage biotechnology company based in Paris, France, dedicated to developing therapeutics that aim to slow degenerative processes linked to aging and enhance functional outcomes for patients with age-related diseases. The company focuses on activating key biological resilience pathways to mitigate the effects of various biological and environmental stresses that contribute to these conditions. Biophytis has two primary drug candidates: Sarconeos (BIO101), an orally administered small molecule being developed for neuromuscular diseases such as sarcopenia and Duchenne muscular dystrophy, and Macuneos (BIO201), also an orally administered small molecule targeting retinal diseases like dry age-related macular degeneration and Stargardt disease. The company has established a collaboration agreement with AFM-Telethon for the development of Sarconeos. Founded in 2006, Biophytis aims to become a leader in aging science by providing innovative therapies to address the needs of patients with limited treatment options.
Web Geo Services
Series A in 2012
Web Geo Services SAS, established in 2009 and headquartered in Montpellier, France, specializes in online mapping and location-based applications. The company focuses on providing location SaaS technology for various sectors, including retail, e-commerce, travel, hospitality, banking, insurance, automotive, and mobility. By leveraging Google Maps, Web Geo Services assists businesses in enhancing customer engagement and driving conversions through digital systems that streamline online checkouts and customer journeys. With a client base of over 400 large companies, it has positioned itself as a leading partner of Google Cloud and the foremost Google Maps partner in Europe, with offices in multiple countries. The company has developed Woosmap, an award-winning platform that enables developers to integrate advanced location intelligence features into mobile applications and websites, thereby offering businesses a competitive edge in their respective markets.
Domain Therapeutics
Venture Round in 2012
Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-Allâ„¢ to identify orthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-Allâ„¢ is able to address difficult GPCRs such as orphan and peptidic GPCRs.
ProTip
Series C in 2012
ProTip SA is a privately held medical device company dedicated to the development of innovative solutions for patients suffering from larynx malfunctions. Its priority focus is to develop a permanent implant for laryngectomized patients. ProTip, based in Strasbourg (Eastern France), was founded in 2004 and has since benefited from strong support from the Alsace region and Oseo, the French public agency for innovation. The company has won several prestigious awards in France. It has established partnerships with a number of academic institutions. The international expansion of the company has recently accelerated due to the ISO certification and CE mark achievement on essential product lines.
Enterome
Series A in 2012
Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, the company specializes in developing innovative disease management solutions that leverage the understanding of the gut microbiome. Enterome focuses on creating biomarkers, companion diagnostics, and therapeutics targeted at microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company’s OncoMimic technology addresses cancer by mimicking tumor-associated antigens, thereby inducing a strong immune response against solid tumors. Enterome's drug candidates are designed to modulate the immune system and are currently advancing through clinical trials, with several programs in Phase 2 targeting challenging cancers such as glioblastoma, adrenal malignancies, and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts.
Streamdata.io
Series A in 2011
Streamdata.io is a developer of real-time API management software focused on event-driven infrastructure. Founded in 2008 and headquartered in Meylan, France, the company, previously known as Mobile Service SAS, operates as a subsidiary of Axway Software SA. Streamdata.io offers three primary services: Distribute, Journey, and Discover. Distribute enables the consumption and publication of events alongside APIs, transforming traditional request/response models into streams of events. Journey provides consulting services and a platform to assist companies in managing their API lifecycle, while Discover helps organizations catalog their digital assets to design effective APIs. The company has collaborated with various partners, including Xignite and Salesforce, to enhance its offerings. Streamdata.io has received multiple accolades, including the European Data Award in 2016 and recognition as a top startup in France. Additionally, the company contributes to industry standards such as AsynchAPI and OpenAPI, emphasizing its commitment to advancing API technology.
Impeto Medical
Series B in 2011
Impeto Medical SAS is a privately owned medical device company based in Paris, France, established in 2005. The company specializes in manufacturing and marketing non-invasive devices that assess eccrine sweat gland activity. Its key products include SUDOSCAN+, which detects and monitors peripheral autonomic neuropathy; EZSCAN, designed for screening and preventing diabetes and cardiometabolic risks; and SUDOSCAN, which evaluates galvanic skin response to assess the sympathetic nervous system's behavior in various conditions, including diabetes and Parkinson's disease. Impeto Medical utilizes patented technology to analyze sudomotor function, enabling healthcare providers to screen large patient populations for early detection of diseases and complications. The company distributes its products through a network of distributors and has subsidiary locations in China and San Diego, California.
Talentsoft
Venture Round in 2011
Founded in 2007, TalentSoft has rapidly established itself as a leader in the SaaS-based talent management sector, particularly in France. The company specializes in cloud-based talent management software, offering a comprehensive suite of services designed to enhance organizations' competency and talent strategies. TalentSoft has formed strategic alliances with key players in the information technology industry, which has contributed to its unique offerings and business growth. With a strong emphasis on partnerships, skilled teams, and innovative technology solutions, the company has garnered the trust of various financial, technology, and sales partners. TalentSoft's credibility is further underscored by its numerous awards and financial backing, enabling it to accelerate its international expansion. The company now operates across all continents, supported by a network of subsidiaries and affiliates in regions including Africa, North America, Asia, and Europe.
Enterome
Seed Round in 2011
Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, the company specializes in developing innovative disease management solutions that leverage the understanding of the gut microbiome. Enterome focuses on creating biomarkers, companion diagnostics, and therapeutics targeted at microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company’s OncoMimic technology addresses cancer by mimicking tumor-associated antigens, thereby inducing a strong immune response against solid tumors. Enterome's drug candidates are designed to modulate the immune system and are currently advancing through clinical trials, with several programs in Phase 2 targeting challenging cancers such as glioblastoma, adrenal malignancies, and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts.
Arlettie
Venture Round in 2010
Arlettie, originally founded as Espace Max in 1993, is based in Paris, France, and specializes in online retail of luxury fashion apparel and accessories. The company operates as an event organizer for private sales and exclusive shopping events, acting as an intermediary between luxury brands and customers. Through its platform, Arlettie offers a curated selection of high-end fashion, accessories, and lifestyle products from renowned brands, facilitating unique shopping experiences for consumers seeking exclusive items.
EffiCity
Series B in 2010
EffiCity SAS is an online real estate agency based in Paris, France, established in 2007. The company specializes in providing a range of real estate services, including the buying and selling of properties, as well as property management and valuation. EffiCity utilizes digital platforms to facilitate transactions, making it easier for clients to navigate the real estate market.
QuesCom
Venture Round in 2010
QuesCom S.A. designs and manufactures Internet telecommunication systems. The company provides business communication management portal, GSM gateway, SIM servers, and mobile call servers. It partners with Aastra, Alcatel, Avaya Inc. & Cisco. QuesCom S.A. was founded in 1999 and is headquartered in Sophia Antipolis, France.
Implanet
Series C in 2010
Implanet S.A. is a French company that designs, manufactures, and sells a range of orthopedic surgical implants and devices. Founded in 2006 and based in Martillac, it operates primarily in France, the United States, Brazil, and other international markets. The company's product offerings include spinal implants, arthroscopic devices, and knee prostheses, with notable products such as the Jazz series for posterior fixation and the Madison knee prosthesis for conventional surgical techniques. Implanet aims to provide high-quality implants that enhance the productivity of healthcare professionals while addressing the need to reduce healthcare costs. Its business model emphasizes social and economic responsibility, ensuring a secure and informative environment for the healthcare community.
Presto Engineering
Venture Round in 2010
Presto Engineering, Inc. is a provider of outsourced development operations for semiconductor and Internet of Things (IoT) device companies. Founded in 2006 and headquartered in San Jose, California, the company specializes in turn-key solutions that encompass radio-frequency (RF), mixed-signal devices, and comprehensive semiconductor testing and analysis services. Its offerings include wafer fabrication, back-end processing, and various backend packaging services. Additionally, Presto Engineering provides extensive product engineering, debugging, and release acceleration services, which cover testing, reliability assessments, and yield enhancement. The company serves a diverse range of sectors, including medical, automotive, industrial, and communications. With additional offices in France, Thailand, and Taiwan, Presto Engineering aims to help clients minimize overhead, reduce risk, and expedite their time-to-market.
Talentsoft
Seed Round in 2009
Founded in 2007, TalentSoft has rapidly established itself as a leader in the SaaS-based talent management sector, particularly in France. The company specializes in cloud-based talent management software, offering a comprehensive suite of services designed to enhance organizations' competency and talent strategies. TalentSoft has formed strategic alliances with key players in the information technology industry, which has contributed to its unique offerings and business growth. With a strong emphasis on partnerships, skilled teams, and innovative technology solutions, the company has garnered the trust of various financial, technology, and sales partners. TalentSoft's credibility is further underscored by its numerous awards and financial backing, enabling it to accelerate its international expansion. The company now operates across all continents, supported by a network of subsidiaries and affiliates in regions including Africa, North America, Asia, and Europe.
Implanet
Series B in 2009
Implanet S.A. is a French company that designs, manufactures, and sells a range of orthopedic surgical implants and devices. Founded in 2006 and based in Martillac, it operates primarily in France, the United States, Brazil, and other international markets. The company's product offerings include spinal implants, arthroscopic devices, and knee prostheses, with notable products such as the Jazz series for posterior fixation and the Madison knee prosthesis for conventional surgical techniques. Implanet aims to provide high-quality implants that enhance the productivity of healthcare professionals while addressing the need to reduce healthcare costs. Its business model emphasizes social and economic responsibility, ensuring a secure and informative environment for the healthcare community.
Webinterpret
Seed Round in 2008
Webinterpret, founded in 2007, aims to make international e-commerce accessible for online sellers. With offices in France, Poland, China, and the USA, the company employs approximately 210 ecommerce specialists who possess extensive local market knowledge. Webinterpret operates a global marketplace that provides services to help online merchants expand their reach internationally. Its platform offers a range of tools, including adjustments to shipping costs, currency conversion, category modifications, precise translations, and international stock management. These services enable online retailers and marketplace sellers to grow their businesses on a global scale and enhance their sales performance.
Codasystem
Venture Round in 2008
Codasystem is a French start-up specializing in digital photography technology that holds legal value. The company provides a real-time monitoring tool that enables users to capture digital photographs using their mobile phones, which can be utilized as legally admissible evidence. This innovative approach enhances the reliability of visual documentation, catering to various sectors that require verifiable photographic records.
TxCell
Series B in 2008
TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in the development of cellular immunotherapies utilizing regulatory T cells (Tregs) to address severe inflammatory and autoimmune diseases. The company's innovative therapies include TX200, a CAR-Treg-based treatment aimed at preventing graft rejection in solid organ transplantation. TxCell is also focused on developing CAR-Treg therapies for conditions such as bullous pemphigoid, multiple sclerosis, and refractory Crohn's disease, with ongoing clinical studies demonstrating promising results. The company collaborates with various research institutions, including the Lübeck Institute of Experimental Dermatology and the University of British Columbia, to enhance its research and development efforts. Additionally, TxCell is a subsidiary of Sangamo Therapeutics, having transitioned from its origins as a spin-off of Inserm, France's National Institute for Health and Medical Research.
Volubill
Series D in 2007
VoluBill S.A. specializes in real-time monitoring, control, and charging software tailored for communication providers. Founded in 2001 and headquartered in Montbonnot Saint Martin, France, the company offers a range of solutions including the CHARGE-IT platform, which facilitates real-time, on-the-network convergent charging and control for data services. Its offerings encompass the CHARGE-IT Service Controller, a platform for network charging, control, and policy enforcement, as well as the CHARGE-IT Dynamic Charging Platform, designed for real-time charging and control across various payment models, such as pre-pay and post-pay. VoluBill serves a diverse clientele that includes fixed, mobile, and fixed mobile convergent operators, with additional offices located in Europe and Asia.
Glowria
Venture Round in 2007
Glowria offers online digital video disc (DVD) rental service. Glowria was founded in 2003 is based in Paris, France.
Idylis
Series B in 2007
Idylis S.A. designs, develops, and markets software solutions for enterprise management. Its products assist in audit and accounting, financial management, documentation, e-mailing, and scheduling applications. The company also offers solutions for commercial applications such as supply chain management, logistics, and inventory management. In addition, it provides customer support and consulting services to its clients. The company was incorporated in 2008 and is based in Issy-les-Moulineaux, France.
DxO Labs
Series A in 2006
DxO Labs SA engages in the development and sale of digital image processing products and solutions in France. Its photography products include DxO Optics Pro, a digital photography software application for image correction and enhancement; and DxO FilmPack that gives digital images the style of the conventional films, and digitally simulates the colors. The company also develops and licenses intellectual property of optics and silicon architectures in the areas of embedded still and video image processing for camera phones and digital cameras. In addition, DxO Labs SA offers DxO Analyzer, an image quality evaluation solution. Its customers include consumer electronics manufacturers, such as digital camera vendors and camera phone vendors; imaging components suppliers, including camera module manufacturers, sensor vendors, and processor vendors; and photographers, as well as photography journalists and imaging experts. The company offers its products through distributors and resellers. DxO Labs SA was formerly known as DO Labs SA. The company was founded in 2002 and is based in Boulogne, France. DxO Labs has additional offices in the United States, Japan, and Korea.
METabolic EXplorer
Series C in 2006
METabolic EXplorer S.A. is an industrial biochemical company based in Saint-Beauzire, France, founded in 1999. The company specializes in developing industrial fermentation processes as sustainable alternatives to petrochemical methods. It focuses on creating functional ingredients derived from natural sources, which are utilized in cosmetics and animal nutrition products, as well as serving as intermediates for synthesizing biomaterials. METabolic EXplorer emphasizes the economic viability of its production processes to enhance competitiveness against traditional petrochemical operations. The company is committed to improving the efficiency of microorganisms and diversifying the supply of renewable raw materials, aiming to produce essential basic chemical compounds with numerous industrial applications.
Aveni
Series B in 2005
Aveni, Inc. specializes in advanced metallization technologies for semiconductor, MEMS, and renewable energy applications. The company offers two primary processes: Electrografting (eG), which is a wet electrochemical method that facilitates the growth of high-quality thin films on conducting surfaces, and Chemicalgrafting (cG), designed for non-conductive substrates. Both technologies have been effectively implemented in manufacturing, demonstrating capabilities at and below the 14 nm technology node and accommodating high aspect ratios. Founded in 2001 as a spinoff from the Commissariat à l’énergie atomique et aux énergies alternatives, Aveni has established partnerships with various research and development centers and leading global manufacturers. Headquartered in Massy, France, the company boasts a skilled team of scientists and engineers with expertise in surface science, chemistry, electrochemistry, physics, materials science, and semiconductors.
Sefas Innovation
Venture Round in 2005
Sefas Innovation was founded in 1991 and has been providing collaborative document composition & production software to Fortune 500 companies for over 15 years. Sefas’ corporate headquarters is in Paris, France, which, along with its UK and US offices, supports over 80 Sefas staff worldwide. Sefas’ Open Print software suite is used by financial services, banking, insurance, utilities, telecoms and public sector organisations for the design, composition and production of B2C documents. These are often complex documents with multiple sources of data; Open Print is unique in its ability to integrate the data from these multiple sources to provide personalized and relevant communications. Increasingly Open Print is being used to redesign mission critical documents so that they can also communicate the latest marketing campaigns and so generate new revenue. The Sefas UK office is based in Bristol and was first opened in 1999. Sefas’ UK clients include Nationwide, EDS Credit Services (Abbey National), HBOS, Inland Revenue, Department of Work & Pensions, Royal & Sun Alliance, RR Donnelley, Bank of Tokyo, DST International and British Telecom who have been using Open Print since (2000).
DSO Interactive
Series B in 2005
DSO Interactive SA designs, develops, and markets software solutions for intermediation of Internet platforms. Its products include auditing and decisional software systems for legal firms. The company also offers information technology and communication consulting services. It was formerly known as Convergence SA and changed its name to DSO Interactive in September 2004. The company was founded in 2001 and is based in Paris, France.
Volubill
Series C in 2005
VoluBill S.A. specializes in real-time monitoring, control, and charging software tailored for communication providers. Founded in 2001 and headquartered in Montbonnot Saint Martin, France, the company offers a range of solutions including the CHARGE-IT platform, which facilitates real-time, on-the-network convergent charging and control for data services. Its offerings encompass the CHARGE-IT Service Controller, a platform for network charging, control, and policy enforcement, as well as the CHARGE-IT Dynamic Charging Platform, designed for real-time charging and control across various payment models, such as pre-pay and post-pay. VoluBill serves a diverse clientele that includes fixed, mobile, and fixed mobile convergent operators, with additional offices located in Europe and Asia.
BoostWorks
Series C in 2003
Established in France in 1989, BoostWorks, Inc. is known worldwide for its creative, high-quality, award-winning network acceleration solutions. Now headquartered in San Francisco, BoostWorks offers a suite of products that immediately solve performance problems experienced by remote users of browser-based applications, without burdening your IT staff or changing your application software infrastructure. This helps global enterprise networks perform faster and more efficiently than ever before. Our products deliver back to your remote users the kind of performance they expect from your wide-area network. BoostWorks' products are sold through its direct sales force, leading systems integrators, distributors, and software vendors with whom it has established worldwide strategic alliances.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.